<DOC>
	<DOCNO>NCT00519233</DOCNO>
	<brief_summary>The present study investigate safety , tolerability spectrum side effect AGS-1C4D4 . As , study characterize dose limit toxicity ( DLT ) potentially maximum tolerate dose ( MTD ) AGS-1C4D4 patient advance HRPC .</brief_summary>
	<brief_title>AGS-1C4D4 Patients With Advanced Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>Cohorts 1-6 patient administer AGS-1C404 sequentially rise dose level . Dose escalation continue MTD AGS-1C4D4 establish maximum plan dose reach .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Patient hormonerefractory metastatic prostate cancer Patient chemotherapy , radiotherapy , biological therapy within past 4 week recover side effect Patient currently participate participate investigational study within past 30 day Patient illness circumstance could limit compliance study requirement Patient use illicit drug recent history drug alcohol abuse within last year Patient Hepatitis B C</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HRPC</keyword>
	<keyword>Advanced hormone refractory prostate cancer</keyword>
</DOC>